Skip to content
10-Q

Quarterly Report

ImmunoGen, Inc.

0001558370-23-007254

← back to feed
Filed
Apr 28, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · Apr 21, 2023 226.07M sh
Capex Q1 2023 · Mar 31, 2023 $209K
Capex Q1 2023 · Mar 31, 2022 $307K
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$73.72M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$41.4M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $201.25M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $275.14M
Stockholders Equity Q1 2023 · Mar 31, 2023 $121.92M
Stockholders Equity Q1 2023 · Dec 31, 2022 $155.83M
Stockholders Equity Q1 2023 · Sep 30, 2022 $178.01M
Stockholders Equity Q1 2023 · Jun 30, 2022 $249.83M
Stockholders Equity Q1 2023 · Mar 31, 2022 $306.47M
Stockholders Equity Q1 2023 · Dec 31, 2021 $325.59M
Current Liabilities Q1 2023 · Mar 31, 2023 $101.63M
Current Liabilities Q1 2023 · Dec 31, 2022 $121.86M
Total Liabilities Q1 2023 · Mar 31, 2023 $166.43M
Total Liabilities Q1 2023 · Dec 31, 2022 $193.11M
Current Assets Q1 2023 · Mar 31, 2023 $243.86M
Current Assets Q1 2023 · Dec 31, 2022 $304.12M
Total Assets Q1 2023 · Mar 31, 2023 $288.35M
Total Assets Q1 2023 · Dec 31, 2022 $348.94M
Eps Basic Q1 2023 · Mar 31, 2023 −$0.16
Eps Basic Q1 2023 · Mar 31, 2022 −$0.10
Sga Expense Q1 2023 · Mar 31, 2023 $40.02M
Sga Expense Q1 2023 · Mar 31, 2022 $16.65M
Rd Expense Q1 2023 · Mar 31, 2023 $51.62M
Rd Expense Q1 2023 · Mar 31, 2022 $44.28M
Net Income Q1 2023 · Mar 31, 2023 −$41.01M
Net Income Q1 2023 · Dec 31, 2022 −$59.01M
Net Income Q1 2023 · Sep 30, 2022 −$77.76M
Net Income Q1 2023 · Jun 30, 2022 −$62.02M
Net Income Q1 2023 · Mar 31, 2022 −$24.15M
Operating Income Q1 2023 · Mar 31, 2023 −$42.39M
Operating Income Q1 2023 · Mar 31, 2022 −$22.85M
Shares Diluted Q1 2023 · Jun 30, 2022 253.26M sh
Shares Diluted Q1 2023 · Jun 30, 2021 199.37M sh
Eps Diluted Q1 2023 · Jun 30, 2022 −$0.34
Eps Diluted Q1 2023 · Jun 30, 2021 −$0.32